|Bid||0.0000 x 900|
|Ask||0.0000 x 2900|
|Day's Range||0.4200 - 0.4770|
|52 Week Range||0.3100 - 2.9700|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2018 - Nov 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.25|
Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, announced today that it has received FDA approval to enroll patients in an ambulance-based Phase 2 clinical trial testing its lead drug, trans sodium crocetinate (TSC), for the treatment of acute stroke. The trial, named PHAST-TSC (Pre-Hospital Ambulance Stroke Trial-TSC), will involve 23 hospitals across urban, suburban, and rural areas in Los Angeles and Central Virginia, working closely with approximately 150 emergency medical transport groups.
Diffusion Pharmaceuticals Inc. (DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on improving patient outcomes in unmet medical needs using its novel small molecule trans sodium crocetinate (TSC), today announced that management will present an overview of the Company and recent advancements of its lead product candidate, trans sodium crocetinate (TSC), at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., on Thursday, September 6, 2018 at 1:45 p.m. Eastern time. To listen to the presentation live, investors may visit the Investor Relations section of Diffusion Pharmaceuticals’ website at www.diffusionpharma.com. An archived webcast of the presentation will also be available on the Company’s website for a period of time.
Early in 2018, Diffusion (DFFN) announced that the first patient has been dosed in the Phase 3 INvestigating Tsc Against Cancerous Tumors (INTACT) clinical trial. The trial is anticipated to screen 300 patients with inoperable glioblastoma multiforme (GBM) and enroll 264 such that results from 236 patients will be available for analysis. Patients will be randomized 1:1 to receive TSC along with standard of care radiation and chemotherapy (temozolimide) or standard of care alone.
Enrollment continues in Phase 3 GBM brain cancer trial Key European patent validated covering oral formulation of TSC Preparing for Phase 2 stroke trial with in-ambulance administration of TSC CHARLOTTESVILLE, ...
In early 2018, Diffusion (DFFN) announced the acceptance of an abstract titled “PreHospital Acute Stroke Therapy with Trans Sodium Crocetinate (PHAST-TSC)” to be presented at the International Stroke Conference. The abstract discussed the design and rationale for a planned Phase 2 study of trans sodium crocetinate (TSC), a small molecule that improves diffusion of oxygen through the bloodstream in order to increase tissue oxygenation, in patients with acute ischemic (from a clot) or hemorrhagic (from a bleed) stroke. The Pre-Hospital Ambulance Stroke Trial – TSC (PHAST-T) will be a randomized, double blind, placebo controlled trial with an anticipated enrollment of 160 ambulance-transported patients treated within two hours of the onset of a suspected stroke.
On April 3, 2018, Diffusion Pharmaceuticals, Inc. (DFFN) announced financial results for 2017 and provided a business update. The primary outcome of the study is overall survival at two years between the two groups.
NEW YORK, NY / ACCESSWIRE / April 3, 2018 / Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (''Diffusion'' or ''the Company''), a clinical-stage biotechnology company focused on extending the life expectancy ...
On January 29, 2018, Diffusion Pharmaceuticals, Inc. (DFFN) announced that the first patient has been dosed in the Phase 3 clinical trial of trans sodium crocetinate (TSC), a small molecule that improves diffusion of oxygen through the bloodstream in order to increase tissue oxygenation and potentially improve outcomes associated with radiation and chemotherapy cancer treatments. The trial has been named INTACT (INvestigating Tsc Against Cancerous Tumors) and is anticipated to screen 300 patients with inoperable glioblastoma multiforme (GBM) and enroll 264 such that results from 236 patients will be available for analysis.
Shares of clinical-stage biotechnology company Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) are crashing – down nearly 40% as of this writing. Diffusion announced this morning that it will be selling at least 15 million shares of its own stock to raise cash for research and development of the company's lead product candidate, transcrocetinate sodium, including clinical trial activities, and for general corporate purposes. Each share of common stock is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.80 per share and accompanying common warrant. The common warrants will be exercisable at an exercise price of $0.80 per share and will expire five years from the date of issuance.
NEW YORK, NY / ACCESSWIRE / January 10, 2018 / Diffusion Pharmaceuticals and Pain Therapeutics were two biotech stocks scorching on Tuesday. Shares of Pain Therapeutics even hit a new high after announcing ...
In this article, I’m going to take a look at Diffusion Pharmaceuticals Inc’s (NASDAQ:DFFN) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
Diffusion Pharmaceuticals Inc (NASDAQ:DFFN), a USD$19.46M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...
If you are looking to invest in Diffusion Pharmaceuticals Inc’s (NASDAQ:DFFN), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...